FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982410008> ?p ?o ?g. }

• W2982410008 endingPage "280" @default.
• W2982410008 startingPage "271" @default.
• W2982410008 abstract "For patients with UC, flexible maintenance dosing therapy may confer advantages for safety, efficacy, costs and patient preference. Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC.To assess the efficacy and safety of tofacitinib dose de-escalation and escalation in patients with UC.We evaluated data (November 2017 data cut-off) from OCTAVE Open, an ongoing, open-label, long-term extension study. The dose de-escalation group comprised 66 tofacitinib induction responders in remission following 52 weeks' tofacitinib 10 mg b.d. maintenance therapy, subsequently de-escalated to 5 mg b.d. in OCTAVE Open. The dose escalation group comprised 57 tofacitinib induction responders who experienced treatment failure while receiving 5 mg b.d. maintenance therapy, subsequently escalated to 10 mg b.d. in OCTAVE Open.After tofacitinib de-escalation, 92.4% (61/66) and 84.1% (53/63) of patients maintained clinical response and 80.3% (53/66) and 74.6% (47/63) maintained remission, at months 2 and 12, respectively. After dose escalation, 57.9% (33/57) and 64.9% (37/57) of patients recaptured clinical response and 35.1% (20/57) and 49.1% (28/57) were in remission, at months 2 and 12, respectively. The incidence rate of herpes zoster with dose escalation (7.6 patients with events/100 patient-years) was numerically higher than in the overall tofacitinib UC programme.Following tofacitinib de-escalation in patients already in remission on 10 mg b.d., most maintained remission, although 25.4% lost remission, at month 12. For induction responders who dose-escalated following treatment failure on 5 mg b.d. maintenance therapy, 49.1% achieved remission by month 12. (ClinicalTrials.gov number: NCT01470612)." @default.
• W2982410008 created "2019-11-08" @default.
• W2982410008 creator A5010011206 @default.
• W2982410008 creator A5012261493 @default.
• W2982410008 creator A5017140014 @default.
• W2982410008 creator A5020827915 @default.
• W2982410008 creator A5022687921 @default.
• W2982410008 creator A5024936486 @default.
• W2982410008 creator A5031466675 @default.
• W2982410008 creator A5032150391 @default.
• W2982410008 creator A5034722460 @default.
• W2982410008 creator A5040354010 @default.
• W2982410008 creator A5047563454 @default.
• W2982410008 creator A5055734737 @default.
• W2982410008 creator A5058934291 @default.
• W2982410008 creator A5062818239 @default.
• W2982410008 creator A5066692640 @default.
• W2982410008 creator A5077199307 @default.
• W2982410008 creator A5080753060 @default.
• W2982410008 date "2019-10-29" @default.
• W2982410008 modified "2023-10-08" @default.
• W2982410008 title "Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open" @default.
• W2982410008 cites W1441706726 @default.
• W2982410008 cites W1973289259 @default.
• W2982410008 cites W1978593886 @default.
• W2982410008 cites W1984705525 @default.
• W2982410008 cites W2008687669 @default.
• W2982410008 cites W2020640954 @default.
• W2982410008 cites W2032473143 @default.
• W2982410008 cites W2119864240 @default.
• W2982410008 cites W2120522488 @default.
• W2982410008 cites W2146692972 @default.
• W2982410008 cites W2171297959 @default.
• W2982410008 cites W2611548364 @default.
• W2982410008 cites W2726676976 @default.
• W2982410008 cites W2791135545 @default.
• W2982410008 cites W2803294938 @default.
• W2982410008 cites W2807009918 @default.
• W2982410008 cites W2900857121 @default.
• W2982410008 cites W2900957065 @default.
• W2982410008 cites W2911490286 @default.
• W2982410008 cites W2919081348 @default.
• W2982410008 cites W2982410008 @default.
• W2982410008 cites W4210662453 @default.
• W2982410008 cites W4295333203 @default.
• W2982410008 doi "https://doi.org/10.1111/apt.15555" @default.
• W2982410008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31660640" @default.
• W2982410008 hasPublicationYear "2019" @default.
• W2982410008 type Work @default.
• W2982410008 sameAs 2982410008 @default.
• W2982410008 citedByCount "58" @default.
• W2982410008 countsByYear W29824100082019 @default.
• W2982410008 countsByYear W29824100082020 @default.
• W2982410008 countsByYear W29824100082021 @default.
• W2982410008 countsByYear W29824100082022 @default.
• W2982410008 countsByYear W29824100082023 @default.
• W2982410008 crossrefType "journal-article" @default.
• W2982410008 hasAuthorship W2982410008A5010011206 @default.
• W2982410008 hasAuthorship W2982410008A5012261493 @default.
• W2982410008 hasAuthorship W2982410008A5017140014 @default.
• W2982410008 hasAuthorship W2982410008A5020827915 @default.
• W2982410008 hasAuthorship W2982410008A5022687921 @default.
• W2982410008 hasAuthorship W2982410008A5024936486 @default.
• W2982410008 hasAuthorship W2982410008A5031466675 @default.
• W2982410008 hasAuthorship W2982410008A5032150391 @default.
• W2982410008 hasAuthorship W2982410008A5034722460 @default.
• W2982410008 hasAuthorship W2982410008A5040354010 @default.
• W2982410008 hasAuthorship W2982410008A5047563454 @default.
• W2982410008 hasAuthorship W2982410008A5055734737 @default.
• W2982410008 hasAuthorship W2982410008A5058934291 @default.
• W2982410008 hasAuthorship W2982410008A5062818239 @default.
• W2982410008 hasAuthorship W2982410008A5066692640 @default.
• W2982410008 hasAuthorship W2982410008A5077199307 @default.
• W2982410008 hasAuthorship W2982410008A5080753060 @default.
• W2982410008 hasBestOaLocation W29824100081 @default.
• W2982410008 hasConcept C126322002 @default.
• W2982410008 hasConcept C141071460 @default.
• W2982410008 hasConcept C197934379 @default.
• W2982410008 hasConcept C2776056953 @default.
• W2982410008 hasConcept C2776694085 @default.
• W2982410008 hasConcept C2777288759 @default.
• W2982410008 hasConcept C2777575956 @default.
• W2982410008 hasConcept C2778283404 @default.
• W2982410008 hasConcept C2778886723 @default.
• W2982410008 hasConcept C2779134260 @default.
• W2982410008 hasConcept C2780479503 @default.
• W2982410008 hasConcept C71924100 @default.
• W2982410008 hasConcept C90924648 @default.
• W2982410008 hasConceptScore W2982410008C126322002 @default.
• W2982410008 hasConceptScore W2982410008C141071460 @default.
• W2982410008 hasConceptScore W2982410008C197934379 @default.
• W2982410008 hasConceptScore W2982410008C2776056953 @default.
• W2982410008 hasConceptScore W2982410008C2776694085 @default.
• W2982410008 hasConceptScore W2982410008C2777288759 @default.
• W2982410008 hasConceptScore W2982410008C2777575956 @default.
• W2982410008 hasConceptScore W2982410008C2778283404 @default.
• W2982410008 hasConceptScore W2982410008C2778886723 @default.
• W2982410008 hasConceptScore W2982410008C2779134260 @default.

• next